STOCK TITAN

INTELLIGENT BIO SOLUTIONS (INBS) SEC Filings, Aug-Sep 2026

INBS NASDAQ

Intelligent Bio Solutions Inc. filings document a medical technology issuer commercializing rapid, non-invasive fingerprint sweat drug screening and reporting through periodic material-event disclosures. Recent 8-Ks cover operating results, preliminary revenue information, Regulation FD presentations, clinical study program updates tied to the Intelligent Fingerprinting Drug Screening System, and manufacturing disclosures for readers and lateral-flow test strips.

The filing record also includes capital-structure and governance subjects, including common stock issued through warrant exercises and an at-the-market offering agreement, restricted stock awards under the 2019 Long Term Incentive Plan and Australian Sub-Plan, and Nasdaq Capital Market bid-price compliance notices. These disclosures frame the company's product commercialization, regulatory pathway, equity compensation, share count and listing-status matters.

Rhea-AI Summary

INTELLIGENT BIO SOLUTIONS INC. (INBS) filed a Form D for a new exempt private offering under Rule 506(b) of Regulation D, covering equity and warrants. The company reports that it has sold $4,979,631 of securities, with no remaining amount offered, and states the offering was closed on September 2, 2026 after a first sale on August 31, 2026.

Ladenburg Thalmann & Co. Inc. acted as placement agent, receiving $399,999.83 in commissions, a $49,999.98 management fee, $60,000 in expense reimbursement, and warrants for 101,832 shares of common stock, plus an ongoing 9% commission on gross proceeds from Series N-1 and N-2 warrant exercises. The issuer is a Delaware corporation in the health care biotechnology sector and declined to disclose its revenue range.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
other
-
Rhea-AI Summary

INTELLIGENT BIO SOLUTIONS INC. (INBS) reports an update to its capital structure. The company states that previously disclosed prefunded warrants were exercised for 285,000 shares of common stock, and 4,333 shares of restricted common stock were issued under an Investor Relations and Corporate Development Advisory Agreement. Following these issuances, the company reports that total outstanding common shares were 3,316,803 as of the close of business on September 10, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
current report
-
Rhea-AI Summary

INTELLIGENT BIO SOLUTIONS INC. (INBS) reports that on September 9, 2026 it submitted a 510(k) premarket notification to the U.S. FDA, seeking regulatory clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The submission is based on a structured 2026 clinical program run with Cliantha Research and CenExel Clinical Research under FDA guidance and ICH GCP standards, including more than 18,000 hours of data collection, 18 detailed test reports, over 170 attachments and more than 15,000 lines of analyzed data.

A key Method Comparison Study showed accuracy above 98%, sensitivity above 94% and 100% specificity, with specimens verified by LC‑MS/MS. Additional usability, interference, precision, and cut-off studies, plus cybersecurity and software documentation resolving all 19 SBOM vulnerabilities and 100% of medium-risk issues, were included. The company frames this as supporting entry into the multi‑billion‑dollar U.S. drug screening market if FDA clearance is obtained, expanding its current non‑U.S. deployments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
current report
Rhea-AI Summary

Intelligent Bio Solutions Inc. (INBS) entered into a private placement with a single institutional investor involving 2,036,659 shares of common stock (or Series M pre-funded warrants in lieu) plus Series N-1 and Series N-2 warrants to purchase up to 2,036,659 shares each, at a combined price of $2.455 per unit, for gross proceeds of approximately $5.0 million before fees. At closing on September 2, 2026, all 2,036,659 units were issued as Pre-Funded Warrants instead of common stock.

Each Pre-Funded Warrant is exercisable for one share at $0.01 per share, and each Series N-1 and N-2 Warrant is exercisable for one share at $2.33 per share, with five-year terms starting when a resale registration statement is declared effective; N-2 warrants become exercisable only after shareholder approval. INBS agreed to file a resale registration statement for the shares and warrant shares by September 15, 2026 and to seek effectiveness by October 15, 2026, and will pay Ladenburg Thalmann a 9% total upfront fee on gross proceeds plus placement agent warrants for 101,833 shares at $3.06875 per share. The company expects to use net proceeds for working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
current report
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. (INBS) reported new clinical performance data for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. In a multi-site U.S. Method Comparison Study, the System achieved overall 98.2% accuracy, 94.6% sensitivity, and 100% specificity across pre-employment and workplace screening settings.

The results, measured against a validated LC-MS/MS reference method, reflect an increase from a prior study that showed approximately 94% accuracy and 82% sensitivity, while maintaining 100% specificity. The company states these data complete the clinical component of its FDA 510(k) package and expects to submit its 510(k) application for the System in September 2026 as part of its planned entry into the U.S. market following FDA clearance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
current report
-
Rhea-AI Summary

INTELLIGENT BIO SOLUTIONS INC. (INBS) furnished an investor presentation under a Regulation FD current report. The company made a presentation about its business and operations available to investors on August 28, 2026, which can be accessed through the Investors section of its website.

The presentation is furnished, not filed, so it is not automatically incorporated into other Securities Exchange Act or Securities Act filings unless specifically referenced there.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
current report
Rhea-AI Summary

Intelligent Bio Solutions Inc. (INBS) reported strong top-line growth for the full year ended June 30, 2026, while remaining significantly loss-making. Revenue reached $4.2 million, a 38% increase year-over-year, driven by a 22% rise in reader installed base to 1,886 units and a 35% increase in consumable cartridges to 106,500 units. Active customers grew to 502.

Gross profit rose to $2.05 million, up 64%, with gross margin expanding from 40.85% to 48.63%, helped by a manufacturing transition to Syrma Johari and a higher mix of cartridge consumables. Cash and cash equivalents increased to $3.99 million from $1.02 million, and total assets were $11.94 million with shareholders’ equity of $5.29 million.

Despite operating improvements, the business generated a sizeable net loss attributable to INBS of $12.43 million, compared with $10.57 million a year earlier, reflecting high selling, general and administrative plus development and regulatory expenses. The company advanced its FDA 510(k) program through multiple clinical, interference, precision, and usability studies and targets a submission in the second half of calendar 2026 to support planned U.S. market entry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.08%
Tags
current report
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. (INBS) is a Delaware-based medical technology company focused on rapid, non-invasive testing, led by its Intelligent Fingerprinting Platform. The IFP System is a fingerprint sweat-based drug screening solution, commercially available in certain non-U.S. markets, serving over 502 mainly U.K. customers in safety-critical industries.

INBS is pursuing FDA 510(k) clearance for its opiate test to enter the U.S. and is expanding across Europe and the APAC region while operating an ISO 13485/9001-certified manufacturing facility in Cambridge, U.K. A 1-for-10 reverse stock split became effective December 15, 2025. As of June 30, 2026, cash and cash equivalents were $3,992,312, and the company reported net losses of $10,568,733 in 2025 and $12,430,975 in 2026. Management and the auditor highlight substantial doubt about INBS’s ability to continue as a going concern without additional capital, and the company discloses risks around future financings, supply concentration, regulatory approvals, and continued Nasdaq listing compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.08%
Tags
annual report
-
Rhea-AI Summary

Intelligent Bio Solutions Inc. received an amended passive ownership report from Armistice Capital, LLC and Steven Boyd. The reporting persons disclose beneficial ownership of 141,397 shares of common stock, representing 5.91% of the class. All 141,397 shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive authority. Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and may be deemed to beneficially own these securities. Steven Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own the same shares. The Master Fund has the right to receive dividends or sale proceeds on the reported securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.67%
Tags
ownership
Rhea-AI Summary

Intelligent Bio Solutions Inc. reported completing its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, a key component of its FDA 510(k) program for U.S. clearance to detect the opiate codeine. All clinical data collection across the FDA 510(k) clinical study program is now finished. The study, conducted under ICH GCP guidelines at three independent U.S. clinical sites over three weeks with 135 participants and nine operator participants, is intended to demonstrate that typical workplace users can operate the system accurately by measuring sensitivity, specificity, and accuracy. The company is analyzing data and assembling its 510(k) submission package, targeting submission in the second half of 2026 ahead of planned entry into the U.S. market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.90%
Tags
current report

FAQ

How many INTELLIGENT BIO SOLUTIONS (INBS) SEC filings are available on StockTitan?

StockTitan tracks 72 SEC filings for INTELLIGENT BIO SOLUTIONS (INBS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for INTELLIGENT BIO SOLUTIONS (INBS)?

The most recent SEC filing for INTELLIGENT BIO SOLUTIONS (INBS) was filed on November 10, 2026.